Stockpickr! Your Source for Stock Ideas

Comments for BMRN

Added By	Comments	Type	Date Added
Brahmsian	9.9	Love	April 27, 2008
Brahmsian	$45.43, $41.00	Love	April 21, 2008
Brahmsian	April 11, 2008	Love	April 11, 2008
barrons2	Q: How about a new recommendation in that area? A: BioMarin Pharmaceuticals [BMRN] has some nice products. It is coming along with some very nice drugs to treat small patient populations, similar to Genzyme [GENZ], where there is not much competition and the drug has a limited market but is necessary for survival.	Love	February 02, 2008
smardeepants	Added 01.02.08	Love	January 02, 2008
smardeepants	Added 01.02.08	Love	January 02, 2008
rbesh	Pipeline	Love	December 07, 2007
mattye21	A couple of niche drugs in the pipeline......good growth...love this stock	Love	December 06, 2007
kschaefour	Healthcare conference Nov.7, FDA approval soon.	Love	October 31, 2007
Michaelid	biotech specializing in rare diseases. Same model as genzyme. Will the latter acquire bmrn? I think so.	Love	October 30, 2007
rbstr44	BioMarin Pharma.--has several drugs that are in the market, and is getting approval for some overseas.	Love	October 29, 2007
mxhunter	Bio marin looks good	Love	October 14, 2007
Vicki Dilworth	New Drug	Love	October 13, 2007
WahnsinnigGeld	featured on M.M.	Love	October 11, 2007
cmacblue42	Sweet Spec play.	Love	October 03, 2007
cmacblue42	Sweet Spec play.	Love	October 03, 2007
swaz7555	produces biopharmaceuticals	Love	September 08, 2007
pantera.group	TOP ANALYST RECOMMENDATION	Love	August 29, 2007
supratrade	BUY	Love	August 25, 2007
supratrade	BUY	Love	August 09, 2007
jdarma	spec drug	Love	May 11, 2007
zachpickr	Currently at the low range, time for a trade.	Love	April 20, 2007
jchatfield	been watching for 3 years	Love	April 11, 2007
GraceM	has good potetial as a niche company with rarer diseases cures.	Love	April 06, 2007
Barrons	From Barron's 4/2/07 "Reiterate Outperform, 22 target. We are incremental buyers after attending American College of Medical Genetics meeting and learning of BMRN's intention to enroll physicians and clinics in expanded-access program for Kuvan, its investigational PKU [metabolic-disorder] drug candidate. While maintaining our estimates, we believe this could provide for a steeper launch than anticipated, should Kuvan be approved in fourth-quarter '07."	Love	March 31, 2007
BIGJIM	pipeline,earnings potential	Love	March 14, 2007
laura labella	jc	Love	March 06, 2007
dfobey	I believed Cramer	Love	February 21, 2007
nikimax	Cramer	Love	February 16, 2007
darogo	another biotech play. feel like it's got potential	Love	February 09, 2007